REP 2165

Drug Profile

REP 2165

Alternative Names: REP 2165 magnesium chelate; REP 2165-Mg

Latest Information Update: 21 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator REPLICor
  • Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B
  • Preclinical Hepatitis D

Most Recent Events

  • 18 Jun 2018 Long term 48-weeks follow-up efficacy data from a phase IIb REP 401 trial in Hepatitis B released by Replicor
  • 13 Apr 2018 Long term 12 weeks follow-up efficacy data from a phase IIb REP 401 trial in Hepatitis B released by Replicor
  • 23 Oct 2017 Interim efficacy data from a phase IIb REP 401 trial in hepatitis B released by Replicor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top